Welcome guest, Login | Register


Joy Y. Feng


Ph.D. in Medicinal Chemistry, University of Florida, College of Pharmacy, 1996

Current position

Senior Research Scientist II, Gilead Sciences, Foster City, CA (2003-present)

Publications (since 2005)

  1. Gaur, V., Vyas, R., Fowler, J. D., Efthimiopoulos, G., Feng, J. Y. and Suo, Z. (2014). Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase. Nucleic Acids Res 42(15): 9984-9995.
  2. Mish, M. R., Cho, A., Kirschberg, T., Xu, J., Zonte, C. S., Fenaux, M., Park, Y., Babusis, D., Feng, J. Y., Ray, A. S. and Kim, C. U. (2014). Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 24(14): 3092-3095.
  3. Feng, J. Y., Cheng, G., Perry, J., Barauskas, O., Xu, Y., Fenaux, M., Eng, S., Tirunagari, N., Peng, B., Yu, M., Tian, Y., Lee, Y. J., Stepan, G., Lagpacan, L. L., Jin, D., Hung, M., Ku, K. S., Han, B., Kitrinos, K., Perron, M., Birkus, G., Wong, K. A., Zhong, W., Kim, C. U., Carey, A., Cho, A. and Ray, A. S. (2014). Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 58(4): 1930-1942.
  4. Kulkarni, R., Feng, J. Y., Miller, M. D. and White, K. L. (2014). Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. Antiviral Res 101: 131-135.
  5. Parrish, J. P., Lee, S. K., Boojamra, C. G., Hui, H., Babusis, D., Brown, B., Shih, I. H., Feng, J. Y., Ray, A. S. and Mackman, R. L. (2013). Evaluation of 2'-alpha-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase. Bioorg Med Chem Lett 23(11): 3354-3357.
  6. Cho, A., Zhang, L., Xu, J., Lee, R., Butler, T., Metobo, S., Aktoudianakis, V., Lew, W., Ye, H., Clarke, M., Doerffler, E., Byun, D., Wang, T., Babusis, D., Carey, A. C., German, P., Sauer, D., Zhong, W., Rossi, S., Fenaux, M., McHutchison, J. G., Perry, J., Feng, J., Ray, A. S. and Kim, C. U. (2014). Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 57(5): 1812-1825.
  7. Arnold, J. J., Sharma, S. D., Feng, J. Y., Ray, A. S., Smidansky, E. D., Kireeva, M. L., Cho, A., Perry, J., Vela, J. E., Park, Y., Xu, Y., Tian, Y., Babusis, D., Barauskus, O., Peterson, B. R., Gnatt, A., Kashlev, M., Zhong, W. and Cameron, C. E. (2012). Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 8(11): e1003030.
  8. Cho, A., Saunders, O. L., Butler, T., Zhang, L., Xu, J., Vela, J. E., Feng, J. Y., Ray, A. S. and Kim, C. U. (2012). Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 22(8): 2705-2707.
  9. Das, K., Bandwar, R. P., White, K. L., Feng, J. Y., Sarafianos, S. G., Tuske, S., Tu, X., Clark, A. D., Jr., Boyer, P. L., Hou, X., Gaffney, B. L., Jones, R. A., Miller, M. D., Hughes, S. H. and Arnold, E. (2009). Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 284(50): 35092-35100.
  10. Koch, K., Chen, Y., Feng, J. Y., Borroto-Esoda, K., Deville-Bonne, D., Gallois-Montbrun, S., Janin, J. and Morera, S. (2009). Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleos Nucleot Nucl 28(8): 776-792.
  11. Paulson, M. S., Yang, H., Shih, I. H., Feng, J. Y., Mabery, E. M., Robinson, M. F., Zhong, W. and Delaney, W. E. t. (2009). Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res 83(2): 135-142. 
  12. Feng, J. Y., Ly, J. K., Myrick, F., Goodman, D., White, K. L., Svarovskaia, E. S., Borroto-Esoda, K. and Miller, M. D. (2009). The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6: 44.
  13. Svarovskaia, E. S., Feng, J. Y., Margot, N. A., Myrick, F., Goodman, D., Ly, J. K., White, K. L., Kutty, N., Wang, R., Borroto-Esoda, K. and Miller, M. D. (2008). The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr 48(4): 428-436.
  14. Ray, A. S., Feng, J. Y., Murakami, E., Chu, C. K., Schinazi, R. F. and Anderson, K. S. (2007). Interaction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. Antivir Chem Chemother 18(1): 25-33. 
  15. White, K. L., Chen, J. M., Feng, J. Y., Margot, N. A., Ly, J. K., Ray, A. S., Macarthur, H. L., McDermott, M. J., Swaminathan, S. and Miller, M. D. (2006). The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 11(2): 155-163.
  16. Feng, J. Y., Myrick, F. T., Margot, N. A., Mulamba, G. B., Rimsky, L., Borroto-Esoda, K., Selmi, B. and Canard, B. (2006). Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleos Nucleot Nucl 25(1): 89-107.
  17. Feng, J. Y., Myrick, F., Selmi, B., Deval, J., Canard, B. and Borroto-Esoda, K. (2005). Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine. Antiviral Res 66(2-3): 153-158.

Book chapter

  1. Feng, J. Y. and Furman, P. A. (2005) Chapter 13, Other Drug Applications. In: Vaghefi, M. (ed). Nucleoside Triphosphates and their Analogs: Chemistry, Biotechnology, and Biological Applications. Taylor & Francis, pp 343-372.
Protocols by Joy Y. Feng
  1. Determination of Mitochondrial DNA Upon Drug Treatment
  2. Mitochondrial Biogenesis Assay after 5-day Treatment in PC-3 Cells